نتایج جستجو برای: dual antiplatelet therapy
تعداد نتایج: 804061 فیلتر نتایج به سال:
conclusions regarding the efficacy outcomes of the patients after des implantation, no differences were found between shorter (≤ 6 months) and longer (≥ 12 months) duration of dapt. what is worse is that longer duration (≥ 12 months) was associated with increased risk of bleeding complications. evidence acquisition this study was conducted at the department of cardiology, the first college of c...
background: combination antiplatelet therapy is a classic treatment for percutaneous coronary intervention (pci) but this therapy increases gastrointestinal bleeding (gib). this study highlights the incidence of related risk factors of gib and endoscopic findings in patients with gib after pci and combination antiplatelet therapy. materials and methods: a standard check list was used to evaluat...
Dual antiplatelet therapy simultaneously blocks different platelet activation pathways and might thus be more potent at inhibiting platelet activation and more effective at reducing major ischemic vascular events compared to antiplatelet monotherapy. Aspirin plus clopidogrel dual therapy is now the standard therapy for patients with acute coronary syndrome and for those undergoing percutaneous ...
For patients with an acute coronary syndrome event, current guidelines recommend dual antiplatelet therapy for at least 12 months after drug-eluting stent placement. However, several clinical trials have assessed whether continuing dual antiplatelet therapy beyond 12 months is beneficial. We review the pros and cons of extending dual antiplatelet therapy.
BACKGROUND/AIMS Dual antiplatelet therapy has to be used for at least 1 month after placement of bare metal coronary stents and for a minimum of 1 year after placement of drug eluting stents. Because of the higher risk of bleeding, guidelines strongly recommend to delay elective surgery until dual antiplatelet therapy is ended. However, no data are available regarding the bleeding risk in patie...
BACKGROUND AND OBJECTIVES Placement of drug-eluting stents (DES) can be complicated by stent thrombosis; prophylactic antiplatelet therapy has been used to prevent such events. We evaluated the efficacy of cilostazol with regard to stent thrombosis as adjunctive antiplatelet therapy. SUBJECTS AND METHODS A total of 1,315 patients (846 males, 469 females) were prospectively enrolled and analyz...
conclusions this investigation might contribute to delineate the best treatment options for this high risk population. evidence acquisition we reviewed current evidences on the use of antiplatelet therapy in patients with esrd/hd undergoing pci, focusing on the efficacy and safety of specific agents and their indications for detailed clinical settings. results clinical setting in hd patients is...
Since platelet activation and aggregation play a major role in thrombus formation in lumen of coronary arteries, they constitute a main target in treatment of stable ischemic heart disease and acute coronary syndromes. Antiplatelet therapy should be commenced as early as possible within the current indications in order to reduce the risk of both acute ischemic complications and recurrent athero...
BACKGROUND Whether triple antiplatelet therapy is superior or similar to dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in the era of drug-eluting stents remains unclear. METHODS AND RESULTS A total of 4203 ST-segment elevation myocardial infarction patients who underwent primary percutaneous co...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید